What Peptides Does Joe Rogan Take? His Full Protocol, the Research Behind Each Compound, and What It All Actually Means

For research and educational purposes only. Not medical advice.

Whether someone loves Joe Rogan, debates him, or stumbles onto his podcast at 2 AM and ends up three hours deep into a conversation about healing compounds, the fact that he has done more to put peptides in front of mainstream America than any clinical publication ever managed is undeniable. When a comedian, UFC commentator, and podcaster with 14.5 million Spotify followers says something works for him, the search traffic proves it.

The question people are typing into Google every day is simple: what peptides does Joe Rogan actually take? This post answers that question completely, covers the research behind every compound in his protocol, and gives readers the honest picture on what the science supports versus what is still being figured out.

One important framing note before getting into the compounds themselves. Rogan is not a physician, researcher, or medical authority. He is a high-profile biohacker who speaks candidly about his personal experience with health optimization tools. That candor has introduced millions of people to compounds that deserve serious attention. It has also, by his own admission, occasionally led him to recommend things to friends with "no research" behind the recommendation. Both things can be true simultaneously. He is an influential voice and an honest one, and neither of those facts means readers should approach any compound without doing their own due diligence.

With that said, here is exactly what he takes, where he has said it publicly, and what the research actually shows.

The Wolverine Stack: BPC-157 and TB-500

If readers have heard Rogan talk about peptides more than once, they have heard him use the phrase Wolverine Stack. He is not subtle about his enthusiasm for this combination, and the story behind it is worth understanding because it explains why he became a peptide advocate in the first place.

Rogan suffered from chronic elbow tendonitis that he described as resistant to conventional treatment. Physical therapy helped temporarily. Rest provided partial relief. The problem kept returning. Then his physician recommended BPC-157. Two weeks later, the tendonitis that had plagued him despite professional treatment was gone. He called it "Wolverine shit" on Andrew Schulz's Flagrant podcast in June 2022 and never really stopped talking about it after that. In January 2026, during JRE episode 2440 with Matt Damon and Ben Affleck, Rogan went in depth on the Wolverine Stack again, calling it the ultimate recovery protocol and sharing accounts of professional athletes returning from soft-tissue injuries in weeks rather than months.

BPC-157

BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice, first isolated and characterized by Dr. Predrag Sikiric at the University of Zagreb in 1993. The fact that it originates from a protein involved in protecting the gastric lining explains its unusual durability against acid degradation and informs its documented GI applications.

The mechanistic research is extensive and well-characterized. BPC-157 promotes angiogenesis through VEGFR2 upregulation and PI3K-Akt-eNOS signaling, creating new blood vessel networks that deliver oxygen and nutrients to injured tissue. It modulates nitric oxide pathways to support vasodilation and cell survival. It sensitizes growth factor receptors including EGFR, PDGFR-beta, and c-Kit to accelerate cellular repair signaling. It reduces neuroinflammation through modulation of dopaminergic and GABAergic systems. Over 150 published preclinical studies document effects across tendon, ligament, muscle, gut, bone, and neural tissue.

Andrew Huberman, during his appearance on Rogan's podcast, explained BPC-157's mechanism clearly: it acts as a repair signal that encourages fibroblasts (the cells that build connective tissue) to migrate to injury sites and lay down new collagen while new blood vessels form to support healing. Huberman also stated the honest caveat plainly: "There isn't any clinical data for BPC-157. It's all animals." That statement remains essentially accurate as of mid-2026. Three published human studies exist, including a 2025 safety study of intravenous BPC-157 in two healthy adults. The animal data is compelling. The human clinical trial base is essentially nonexistent.

Regulatory status: BPC-157 is among the peptides scheduled for formal PCAC review on July 23, 2026, for potential inclusion on the FDA's 503A Bulk Drug Substances List. A positive PCAC recommendation would allow licensed compounding pharmacies to legally prepare BPC-157 with patient-specific prescriptions. Final regulatory resolution through the rulemaking process would follow in 2027 or later. As of mid-2026, it remains in Category 2 restricted status pending that review.

TB-500

TB-500 is the synthetic fragment of Thymosin Beta-4 that Rogan pairs with BPC-157 to complete the Wolverine Stack. Thymosin Beta-4 is a naturally occurring 43-amino-acid protein found in virtually every human cell, where it serves as the primary regulator of G-actin, the monomeric form of actin that polymerizes into the structural and motility filaments that define how cells move, communicate, and repair.

The mechanism is distinct from BPC-157 in a way that matters practically. Where BPC-157 primarily drives angiogenesis and growth factor receptor signaling, TB-500 operates through actin dynamics, regulating the pool of free actin available for polymerization to facilitate cell migration, wound closure, and tissue remodeling. It also promotes epithelial-to-mesenchymal transition in cardiac tissue following ischemia-reperfusion injury and activates integrin-linked kinase (ILK) pathways involved in cardiac cell survival. These are mechanistically separate from BPC-157's vascular effects, which is the legitimate scientific basis for the "synergistic" framing Rogan applies to the combination.

The research base covers skeletal muscle repair, connective tissue remodeling, corneal wound healing, and cardiac applications. The honest assessment mirrors BPC-157: the preclinical mechanistic picture is solid; the human clinical trial data is essentially absent as of mid-2026. TB-500 is also scheduled for PCAC review on July 23, 2026, under the wound healing indication.

Ipamorelin and CJC-1295

Rogan named ipamorelin specifically in his June 2022 Flagrant appearance as one of his three primary peptides, describing it as something that helps the body produce growth hormone as it did at a younger age. The typical research pairing, and the combination Rogan references, combines ipamorelin with CJC-1295.

Ipamorelin is a pentapeptide (five amino acids) that functions as a selective growth hormone secretagogue (GHS). It binds the ghrelin receptor (GHS-R1a) in the pituitary gland to stimulate natural growth hormone pulse release. What makes it distinctive within the GHS category is selectivity: unlike older GHRPs, ipamorelin stimulates growth hormone release without meaningfully elevating cortisol or prolactin. This cleaner hormonal profile is why it has become the preferred GHS in clinical research and physician-directed protocols.

CJC-1295 is a growth hormone releasing hormone (GHRH) analog, explicitly named on WADA's Prohibited List and explicitly named in the FDA's 503A compounding framework categories. It extends the half-life of GHRH signaling dramatically, from minutes to days, by binding albumin through its Drug Affinity Complex (DAC) modification. When combined with ipamorelin, CJC-1295 amplifies the GHRH signal that prepares the pituitary to release GH, while ipamorelin provides the GHS signal that triggers the actual pulse. The combination produces a more robust and sustained GH pulse than either compound alone.

A 2006 Phase I trial published in the Journal of Clinical Endocrinology and Metabolism documented that CJC-1295 produced dose-dependent GH and IGF-1 elevation with no serious adverse events across a small number of subjects. That is a safety study, not an outcomes trial, and it represents essentially the sum total of published human clinical data for this pairing. The mechanistic rationale is sound; the clinical evidence base for outcomes in healthy aging adults is still in early territory.

Rogan's framing of this combination, that it helps the body produce the hormones it would have produced at a younger age, is mechanistically accurate in the sense that it stimulates endogenous pituitary GH release rather than replacing GH directly. Whether that downstream GH amplification produces the outcomes biohackers seek at typical research doses is the question the clinical evidence has not yet definitively answered.

Important WADA note: CJC-1295 is specifically named as a prohibited substance under S2.2.4 of the 2026 WADA Prohibited List. Ipamorelin falls under the GHS category prohibited under the same section. Any competitive athlete under WADA jurisdiction needs to understand that both compounds are prohibited at all times, in-competition and out-of-competition.

Thymosin (Thymosin Alpha-1 and Thymosin Beta-4)

In his Flagrant appearance, Rogan named "Thymosin" as his third compound alongside BPC-157 and ipamorelin. The Thymosin family includes two distinct research peptides that serve different purposes and get discussed in overlapping ways in the community.

Thymosin Alpha-1 is an immune modulation peptide derived from thymosin fraction 5, originally isolated from the thymus gland. It is approved as a pharmaceutical drug called Zadaxin in more than 35 countries for the treatment of hepatitis B, hepatitis C, and as an immunoadjuvant in certain cancers. Its mechanism centers on T-cell maturation and differentiation, enhancing the adaptive immune response without the systemic inflammatory signals that pro-inflammatory approaches can trigger. For a 57-year-old with a demanding physical and travel schedule, immune modulation has practical appeal beyond the athletic recovery narrative.

Thymosin Beta-4 is the parent molecule of TB-500 discussed above. Rogan sometimes references Thymosin in the context of the Wolverine Stack, which creates some ambiguity in tracking which specific thymosin compound he is using at any given time. The distinction matters mechanistically: Thymosin Alpha-1 is primarily immune-focused, while Thymosin Beta-4 and its derivative TB-500 are primarily tissue repair and actin-dynamics compounds.

Sermorelin

Earlier in Rogan's public discussion of his protocol, he referenced sermorelin alongside BPC-157. Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (growth hormone releasing hormone), meaning it stimulates the pituitary gland to produce and secrete its own GH rather than providing exogenous GH. It has a shorter half-life than CJC-1295, which typically means less sustained GH elevation but also a more physiological pulse pattern that more closely mimics the body's natural GH secretion rhythms.

Sermorelin is explicitly named on WADA's Prohibited List under S2.2.4 GHRH analogs. It is also one of the compounds the FDA evaluated and named specifically in its compounding framework proceedings. For Rogan's purposes, it appears to have been part of an earlier phase of his protocol that shifted toward ipamorelin and CJC-1295 as those compounds became more central to the conversation.

Retatrutide

In December 2025, JRE episode 2421 with Derek from More Plates More Dates included discussion of retatrutide, the triple-agonist GLP-1/GIP/glucagon receptor compound in Phase 3 clinical trials that has produced the most dramatic weight reduction data of any compound in its class. Rogan's interest in retatrutide reflects the broader conversation in the biohacking and health optimization community about where the GLP-1 class is going beyond semaglutide and tirzepatide.

Retatrutide is not a compound Rogan has confirmed using personally. The discussion was in the context of what is emerging in the clinical trial landscape. Phase 2 data showed approximately 24.2 percent weight reduction at 48 weeks in the highest-dose group, a number previously associated with bariatric surgery rather than pharmaceutical intervention. That data is what generates the conversation.

MOTS-c

Also mentioned in the December 2025 More Plates More Dates episode, MOTS-c is a mitochondria-derived peptide encoded in mitochondrial DNA that activates AMPK to drive glucose uptake in skeletal muscle independent of insulin signaling. It is among the longevity compounds generating the most legitimate scientific excitement in 2026, with a 2025 Nature publication expanding its documented role in cellular aging biology.

MOTS-c is scheduled for PCAC review on July 23, 2026, under the obesity and osteoporosis indication. Rogan's mention reflects his engagement with the frontier of longevity science rather than a confirmed personal protocol compound.

The Quality Problem Rogan Himself Raised

Here is something that gets lost in the enthusiasm around Rogan's peptide endorsements. In multiple podcast discussions, Rogan himself has flagged that a lot of people are getting bogus peptides. He did not say that the compounds do not work. He said that what many people are buying and injecting may not be what they think it is.

He is not wrong about this. Data from independent testing platforms showed approximately 30 percent of gray market research peptides in 2025 were mislabeled, under- or over-dosed, or contaminated. Imports of hormone and peptide compounds from China doubled to $328 million in 2025, a significant portion moving through channels with no quality verification whatsoever.

The compounds Rogan discusses are compelling enough to take seriously. Taking them seriously means sourcing them from vendors with documented independent third-party testing covering identity, purity, endotoxins, sterility, and content. A QR code on every vial linking to a batch-specific COA from a named, independent laboratory is the minimum standard worth accepting. Everything else is guessing.

That is exactly what the RUO Codes vendor directory is built to help readers navigate. Every vendor in the approved directory meets a defined testing minimum before they earn a listing. Because if Joe Rogan's experience with elbow tendonitis taught the research community anything, it is that these compounds can produce remarkable results, but only if what is in the vial is actually what it claims to be.

For vetted vendors, current coupon codes, and active sale information, visit RUO Codes' vendor directory. Details of an active vendor promotion appear on the Active Sales tab.

For research and educational purposes only. Not medical advice. Research peptides are not FDA-approved for human use. Regulatory status of specific compounds may have changed since the date of this publication.